Division of Sanofi
Latest From Ablynx NV
The US Nasdaq exchange has become the only option for ambitious UK and European biotechs.
Novartis' Zolgensma and Pfizer's Vyndaqel were two of the early commercial standouts in 2019, on a likely blockbuster trajectory, while AbbVie's Skyrizi is poised to be fierce competitor in psoriasis.
AstraZeneca emerged as big pharma’s most active dealmaker over the 2014-2018 period, thanks to a combined surge in both in-licensing and out-licensing agreements.
Datamonitor report highlights big pharma’s licensing trends from last five years, and finds UK firm top on numbers of deals, but Merck & Co put up most money.
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Western Europe
- Parent & Subsidiaries
- Senior Management
Edwin Moses, PhD, CEO
Wim Ottevaere, CFO
Markus Ewert, PhD, CBO
Robert K Zeldin, MD, CMO
Heylen Johan, Chief Commerical Officer
Robert Friesen, PhD, CSO
- Contact Info
Phone: (32) 9 262 00 00
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.